2014
DOI: 10.1177/1545968314521695
|View full text |Cite
|
Sign up to set email alerts
|

Prediction and Stratification of Upper Limb Function and Self-Care in Acute Cervical Spinal Cord Injury With the Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP)

Abstract: The GRASSP at 1 month can accurately predict upper limb function and self-care outcomes even in a heterogeneous group of individuals across a wide spectrum of neurological recovery. The application of URP-CTREE can reveal the distribution of outcome categories and, based on this, inform trial protocols with respect to outcomes analysis and patient stratification.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

4
38
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
5
3

Relationship

2
6

Authors

Journals

citations
Cited by 41 publications
(42 citation statements)
references
References 44 publications
4
38
0
Order By: Relevance
“…Experimental treatments against these impediments have resulted in first-in-man phase-I trials for human SCI including anti-Nogo-A antibody treatments [7], stem cell transplantation (HuCNS-SC: NCT01321333 identified in ClinicalTrials.gov) and drug administration (Riluzole: NCT00876889 identified in ClinicalTrials.gov; Minocycline: identified as NCT00559494 in ClinicalTrials.gov; for a review, see [8]). Although much has been learned from these trials, they suffer from a lack of adequate outcome assessments and sensitive biomarkers with the potential to stratify the highly diverse patients into homogenous cohorts and validate the efficacy of drugs [9,10]. To enable efficient translation, these interventions require biomarkers that can be used as surrogate makers of safety and efficacy of agents in a timely and economical manner [11].…”
Section: Introductionmentioning
confidence: 99%
“…Experimental treatments against these impediments have resulted in first-in-man phase-I trials for human SCI including anti-Nogo-A antibody treatments [7], stem cell transplantation (HuCNS-SC: NCT01321333 identified in ClinicalTrials.gov) and drug administration (Riluzole: NCT00876889 identified in ClinicalTrials.gov; Minocycline: identified as NCT00559494 in ClinicalTrials.gov; for a review, see [8]). Although much has been learned from these trials, they suffer from a lack of adequate outcome assessments and sensitive biomarkers with the potential to stratify the highly diverse patients into homogenous cohorts and validate the efficacy of drugs [9,10]. To enable efficient translation, these interventions require biomarkers that can be used as surrogate makers of safety and efficacy of agents in a timely and economical manner [11].…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, moderate neurologic improvements may get masked by spontaneous neurologic recovery early after injury, especially in patients with incomplete SCI. [2][3][4] Thus, larger sample sizes are required or potential study participants have to be excluded. Furthermore, primarily eligible patients have to be excluded as a result of severe concomitant injuries (for example, head trauma) or comorbidities, mental disorders, psychoactive substance abuse or communication barriers (for example, foreign languages), which preclude obtaining informed consent or represent confounding factors.…”
Section: Introductionmentioning
confidence: 99%
“…The prevalence of incomplete injuries is greater and the conversion rates from AIS A to B, C, or D are higher than previously reported. 7 The impact of motor recovery in SCI has been used to predict independence as it relates to scores on the Spinal Cord Independence Measure (SCIM); 8,9 however, the impact of early neurological recovery (0-3 months) and conversion as they relate to upper limb and hand function have yet to be explored. Some work has been done to explore the relationship between ISNCSCI upper extremity motor scores (UEMS) to the self-care subscale of the SCIM, which identifies clinically meaningful change.…”
Section: Introductionmentioning
confidence: 99%